On-demand education

Prostate Cancer
Type

Prof. Nicolas Mottet about the changes in the 2022 guidelines for prostate cancer - Part 2

Duration: 21 minutes

Prof. Nicolas Mottet about the changes in the 2022 guidelines for prostate cancer - Part 1

Duration: 15 minutes

Advanced Prostate Cancer – Non-Metastatic Hormone-Sensitive Prostate Cancer (nmHSPC)

Duration: Approx. 120 minutes

PARP inhibitors in prostate cancer. Part 2

Duration: 70

Paradigm shifts in metastatic hormone sensitive prostate cancer (mHSPC): Recent treatment developments

Duration: Approx 60 minutes

Management of Non-metastatic Castration Resistant Prostate Cancer (nmCRPC): Putting current evidence into practice

Duration: Approx. 50 minutes

Artificial intelligence: The role for research and patient treatment

Duration: Approx. 70 minutes

UROwebinar: PARP inhibitors in prostate cancer. Part 1

Duration: Approx. 60 minutes

Identification and management of patients with nmCRPC

Duration: Approx. 60 – 90 minutes

Future directions in PCa management

Duration: Approx. 60 – 90 minutes

Prostate cancer: Aftercare should not be an afterthought

Duration: Approx. 60 minutes

From clinical trial (ARAMIS, PROSPER, SPARTAN) to Real life. How to identify nmCRPC patient that can benefit from 2nd Gen ARIs?

Duration: Approx. 60 – 90 minutes

Prof. Nicolas Mottet on new guideline recommendations for prostate cancer - Part 2

Duration: 14 min

Prof. Nicolas Mottet on new guideline recommendations for prostate cancer - Part 1

Duration: 14 min

Advances in safety in the treatment of PCa

Duration: Approx. 60 – 90 minutes

Imaging and PSA assessment in nmCRPC patients and the treatment consequences

Duration: Approx. 60 – 90 minutes